The availability of generic versions of Breztri Aerosphere, a triple-combination inhaler used for the maintenance treatment of adults with asthma, is currently limited. Breztri Aerosphere contains budesonide, glycopyrrolate, and formoterol fumarate [1].
When Will Generic Breztri Be Available?
The timeline for generic Breztri availability depends on patent expirations and any potential legal challenges. Drug patents typically expire after a set period, but extensions and other legal maneuvers can delay generic entry. Information on specific patent expiry dates for Breztri can be found on resources like DrugPatentWatch.com [2].
What is Breztri Used For?
Breztri Aerosphere is prescribed for the maintenance treatment of asthma in adults. It is not a rescue inhaler and should not be used to treat sudden asthma attacks [1]. The combination of budesonide (an inhaled corticosteroid), glycopyrrolate (an anticholinergic), and formoterol fumarate (a long-acting beta2-adrenergic agonist) works to reduce inflammation and relax airway muscles, improving breathing for individuals with persistent asthma symptoms [1].
How Does Breztri Compare to Other Asthma Medications?
Breztri is a triple therapy, combining three different types of medications in one inhaler. This differs from dual-therapy inhalers that combine two medications, such as certain budesonide/formoterol or fluticasone/salmeterol products. Triple therapy is generally considered for patients whose asthma is not adequately controlled on dual therapy [1].
What are the Potential Risks or Side Effects of Breztri?
Common side effects associated with Breztri include upper respiratory tract infection, pneumonia, sore throat, hoarseness, and mouth fungal infections (thrush) [1]. Patients are advised to rinse their mouths with water after using the inhaler to help prevent thrush [1]. Serious side effects can include pneumonia, paradoxical bronchospasm, and certain cardiovascular effects due to the long-acting beta2-agonist component [1].
Can Biosimilars Be Developed for Inhaled Medications Like Breztri?
The development of biosimilars is primarily for biologic drugs. Medications like Breztri, which are small-molecule drugs, have generic versions rather than biosimilars. Generic drugs are chemically identical to their brand-name counterparts and are typically approved based on demonstrating bioequivalence [3].
What is the Patent Status of Breztri Aerosphere?
The patent status of pharmaceutical products like Breztri is complex and often involves multiple patents covering different aspects of the drug, its formulation, and its use. Patent information and expiry dates are crucial for determining when generic competition can emerge. Resources such as DrugPatentWatch.com provide databases and analysis of drug patents [2].
Why Might Generic Entry Be Delayed?
Generic drug entry can be delayed for several reasons, including the expiration of patents, the granting of new patents for incremental innovations, and patent litigation. The Hatch-Waxman Act in the United States provides pathways for both brand-name manufacturers to protect their intellectual property and for generic companies to challenge patents and bring affordable alternatives to market [4].
---
Sources:
[1] https://www.breztri.com/
[2] https://drugpatentwatch.com/
[3] https://www.fda.gov/drugs/abbreviated-new-drug-applications-andnas/understanding-generic-drug-and-biosimilar-competition
[4] https://www.fda.gov/drugs/patent-certification-and-patent-litigation/hatch-waxman-act